The rules haven’t changed overnight, but the way they’re being enforced has.
Across the food and beverage industry, regulators are increasing scrutiny of labels, marketing claims, imported products, and ingredients. At the same time, states are moving faster than ever on new food legislation, creating a more complex compliance landscape for national brands.
FDA warning letter activity has increased for three straight years. Through late July, the agency issued 363 warning letters in 2026, ahead of the same period in 2025 (354), 2024 (321), and 2023 (293). June alone produced 86 warning letters, making it the busiest month of the year.
For brands, compliance is no longer just about reviewing a label before launch. It requires understanding where enforcement is headed and identifying potential risks before they become recalls, warning letters, or lawsuits.
The Same Compliance Mistakes Keep Happening
Despite new enforcement priorities, the most common compliance failures remain surprisingly familiar. Many recalls still come down to one problem: the label doesn’t accurately reflect what’s inside the package.
Undeclared allergens account for 85 of the 237 FDA food recalls tracked so far in 2026, more than any other cause. The breakdown is a checklist of quality-control gaps: milk missed on 20 labels, soy on 19, sesame and wheat on 9 each, egg on 8, and peanut on 6. Sometimes it’s all of them at once: in late July, Lidl US recalled its imported private-label shortbread cookies for undeclared wheat, soy, milk, egg, and tree nuts.
Sesame keeps tripping up brands three years after the FASTER Act made it the ninth major allergen, and often in the products where it should be most obvious: 2026 opened with a hummus maker recalling multiple varieties for undeclared sesame. Another 10 recalls cite undeclared color additives, and 35 involve foreign material such as metal, glass, or plastic, a growing byproduct of the co-manufacturing boom.
Food safety trends have shifted, as well. Salmonella has driven 44 recalls so far in 2026, closing in on its 53 for all of 2025, while Listeria recalls collapsed from 55 last year to 8. Much of the Salmonella surge traces to a single contaminated milk-powder supplier that cascaded recalls through dozens of downstream products this spring, reaching household names like Ghirardelli’s powdered beverage mixes. FDA is also increasing its focus on supplier oversight. Warning letters citing Foreign Supplier Verification Program (FSVP) violations have risen from 18 at this point last year to 42 in 2026, making supplier verification one of the agency’s largest food enforcement priorities.
The financial impact remains significant. Industry estimates place the average direct cost of a recall at roughly $10 million before legal expenses, lost sales, and damage to brand reputation.
Regulators Are Looking at More Than Your Label
One of the biggest changes in recent years is where the FDA finds violations.
Investigators increasingly rely on publicly available marketing materials rather than on-site inspections. Company websites were cited in 218 of the 247 published FDA warning letters analyzed in 2026. Social channels get read, too: FDA cited Facebook in 22 letters and Instagram in 12 during 2024, then 16 and 19 respectively in 2025, along with Amazon product listings.
In an April 2026 letter to a supplement marketer, the agency noted that it had reviewed the company’s Facebook page on its way to cataloging heart-disease and diabetes treatment claims on the website it linked to. In a December letter to another supplement seller, investigators walked through the website and Instagram account product by product.
For brands, packaging is no longer the only compliance concern. Every consumer-facing claim, whether it appears on a website, retailer listing, email campaign, or Instagram post, has become part of the regulatory review.
Marketing Claims Are the New Enforcement Frontier
Historically, FDA warning letters focused on manufacturing issues such as sanitation, GMP compliance, and HACCP requirements. In 2026, marketing claims have become one of the fastest-growing enforcement priorities.
The clearest example is FDA’s campaign against compounded GLP-1 weight-loss products. The agency issued more than 50 warning letters to telehealth companies during two coordinated enforcement waves this year, challenging claims that compounded semaglutide and tirzepatide products were equivalent to brand-name drugs or “FDA-approved.” The June letters, like this one to a med-spa’s weight-loss program, quote the companies’ own websites line by line.
Weight-loss drugs may feel distant from food and beverage, but the enforcement logic isn’t. Functional beverages, protein products, and anything positioned near weight management or blood sugar sits close to the same claim lines the agency is now policing at scale. A July letter to a supplement maker shows the food-side version of the same playbook: neuropathy-relief claims on the company’s website turned its dietary supplements into unapproved new drugs in the agency’s eyes.
The plaintiffs’ bar is running the same play. Federal dockets show 93 baby-food heavy-metals suits filed this year against four in the same window last year, a 99-case cluster naming the category’s biggest manufacturers, with new complaints still arriving in late July. Suits challenging “natural” and “organic” label claims number 14, with 6 filed this year versus 1 by this point in 2025, and a 15-case cluster over ultra-processed ingredients and synthetic additives is growing on the same curve. Class-action complaints increasingly quote the same public marketing language FDA quotes, so one weak claim now draws fire from two directions.
States Are Moving Faster Than Federal Rulemaking
While federal rulemaking grinds forward, statehouses have become the fastest-moving food regulators in America. Eighteen states have acted on food-ingredient-restriction bills so far in 2026, led by New York, West Virginia, Iowa, and New Jersey. Of the roughly 150 active food bills Truli tracks, 98 saw legislative action this year and 12 have passed or been enrolled.
The targets are remarkably consistent. Red 40 appears in 57 tracked bills, Yellow 6 in 54, and Red 3, Blue 1, and Blue 2 in 53 each, alongside potassium bromate (46 bills), brominated vegetable oil (33), and titanium dioxide (29). West Virginia’s first-in-the-nation retail dye ban, signed in March 2025 and effective January 2028, was temporarily blocked by a federal court in December, a reminder that the patchwork will be litigated even as it expands.
FDA is converging on the same ingredients from the federal side. Color additives appear in 12 of the 36 food-related Federal Register documents the agency has published this year, more than any other topic, including a July proposal to revoke Citrus Red 2, and fast-tracked listings for natural replacements like beetroot red and spirulina extract.
For a national brand, this is no longer a monitoring problem. It’s a portfolio-planning problem. A formulation that’s legal in 49 states and restricted in one still forces a reformulate-or-relabel decision across the whole SKU, and the deadlines arrive state by state, not all at once.
From Monitoring to Predicting Risk
Many of today’s biggest enforcement trends were visible long before they became industry headlines.
Supplier verification violations increased steadily before becoming one of FDA’s largest enforcement categories. State legislatures introduced nearly identical ingredient restriction bills across the country. Marketing-focused warning letters expanded well before FDA’s coordinated GLP-1 enforcement campaign.
That shift is changing how regulatory teams operate. Rather than simply monitoring regulations as they’re released, leading companies are beginning to use enforcement data to identify emerging risks before they become compliance issues.
The analysis in this report is part of Truli’s broader regulatory intelligence platform, which continuously analyzes FDA warning letters, recalls, lawsuits, state legislation, guidance documents, and other regulatory developments across the food, beverage, and supplement industries. By connecting those enforcement trends to a company’s labels, packaging, formulations, marketing materials, and product portfolio, Truli helps regulatory teams understand where they may be exposed before issues become recalls, warning letters, or litigation.
Instead of asking what changed this week?, regulatory teams can start asking different questions, such as:
- Which enforcement trends are accelerating?
- Which products or claims are most exposed?
- What should we fix before regulators identify it?
Regulatory enforcement in 2026 is faster, more coordinated, and increasingly data driven. The companies that stay ahead will not simply respond more quickly. They will recognize emerging patterns earlier, understand how those patterns affect their products, and address potential risks before regulators do.
10 Key Takeaways
- FDA enforcement is picking up, with warning letters rising for three years in a row and more scrutiny across the food and beverage industry
- Basic compliance mistakes are still causing major problems, with undeclared allergens continuing to drive more recalls than any other issue
- Supplier compliance is getting more attention, as FDA increases enforcement around imported products and whether companies are properly verifying their suppliers
- Compliance now extends well beyond the product label, with regulators reviewing websites, social media, retailer listings, and other public-facing marketing
- Marketing claims are becoming a bigger source of risk, especially when brands make claims related to health conditions, weight management, or other product benefits
- The same claims can create both regulatory and legal exposure, as lawsuits increasingly focus on the same marketing language that regulators are questioning
- State regulations are becoming harder to manage, with more states introducing their own restrictions on food dyes, additives, and other ingredients
- New state rules can affect an entire product portfolio, since a restriction in one major market can force brands to reformulate or relabel products nationwide
- Enforcement data can provide an early warning of where regulation is headed, since many of today’s major enforcement priorities were visible in the data before becoming broader industry issues
- Compliance is shifting from reacting to problems to anticipating them, with brands increasingly needing to understand which products, ingredients, and claims could become risks before regulators act
*Enforcement statistics are from Truli’s analysis of FDA, USDA, federal court, and state legislative data, August 2026.*
